Triple Combination Therapy for Richter’s Transformation
August 8, 2024
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
CLL Society awarded Dr. Prajish Iyer a research grant for his project studying Richter’s transformation, a rare but aggressive progression of CLL.
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
Great progress has been made in how we manage chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), so much so that patients may now have a normal life expectancy. But there is still much left to do.
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
This new research identifies some of the genetic changes that drive the evolution of CLL to Richter’s syndrome.
Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).
Some see CLL / SLL as a solved problem. But unfortunately, we know better. This abstract from the European Hematology Association (EHA) Annual Congress in 2022 reinforced one of our greatest unsolved problems: what happens following treatment with a covalent BTK and BCL2 inhibitor.